| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/27/2008 | EP1890994A2 Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine |
| 02/27/2008 | EP1890993A2 Benzoic acid derivatives that are modulators or antagonists of glyr |
| 02/27/2008 | EP1890767A2 Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| 02/27/2008 | EP1890732A1 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 02/27/2008 | EP1890729A2 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors |
| 02/27/2008 | EP1890728A1 Combination of hmg-coa reductase inhibitors amd mtor inhibitors |
| 02/27/2008 | EP1890712A1 Compositions and methods for treating pain |
| 02/27/2008 | EP1890711A1 Compounds for treating or preventing amine oxidase related diseases or disorders |
| 02/27/2008 | EP1890710A1 Production of glucosamine from plant species |
| 02/27/2008 | EP1890709A2 Production of glucosamine from plant species |
| 02/27/2008 | EP1890708A1 Glucose inducible insulin expression and methods of treating diabetes |
| 02/27/2008 | EP1890707A2 Nutritional supplement with colostrum and epa or dha or gla |
| 02/27/2008 | EP1890706A2 Process for the preparation and isolation of phosphatides |
| 02/27/2008 | EP1890705A1 Use of 24-nor-udca |
| 02/27/2008 | EP1890704A1 Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen |
| 02/27/2008 | EP1890703A2 Pyrimidine compounds |
| 02/27/2008 | EP1890702A1 Use of cyanopyrimidines for the treatment of cardiovascular diseases |
| 02/27/2008 | EP1890701A1 Composition for the treatment of multiple sclerosis |
| 02/27/2008 | EP1890700A2 Methods and compositions for managing psychotic disorders |
| 02/27/2008 | EP1890699A1 Indacterol derivatives and phosphodiesterase inhibitors for the treatment of airway diseases |
| 02/27/2008 | EP1890698A1 A method of manufacturing a nicotine delivery product |
| 02/27/2008 | EP1890697A2 Azinone and diazinone v3 inhibitors for depression and stress disorders |
| 02/27/2008 | EP1890696A2 Novel 3-spirocyclic indolyl derivatives useful as orl-1 receptor modulators |
| 02/27/2008 | EP1890695A2 Use of 2,5-disubstituted thiazol-4-one derivatives in drugs |
| 02/27/2008 | EP1890694A1 Phenylalkyl substituted heteroaryl devivatives |
| 02/27/2008 | EP1890693A2 Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases |
| 02/27/2008 | EP1890692A1 Formulations of lipoic acid and hyaluronic acid and/or the derivatives thereof in the pharmaceutical and cosmetic fields |
| 02/27/2008 | EP1890691A2 Compositions comrising nebivolol |
| 02/27/2008 | EP1890690A2 Mao-b inhibitors useful for treating abesity |
| 02/27/2008 | EP1890689A2 Composition for slowing down the development of alzheimer's disease |
| 02/27/2008 | EP1890688A2 Nutritional method |
| 02/27/2008 | EP1890687A1 Stable pharmaceutical gel of diclofenac sodium |
| 02/27/2008 | EP1890686A1 Peritoneal dialysis fluid |
| 02/27/2008 | EP1890685A2 Pharmaceutical formulations of amyloid inhibiting compounds |
| 02/27/2008 | EP1890684A1 Treatment of sleep-wake disorders |
| 02/27/2008 | EP1890683A1 Methods of supressing uv light-induced skin carcinogenesis |
| 02/27/2008 | EP1890681A2 Method and composition for pharmaceutical product |
| 02/27/2008 | EP1890680A2 Diclofenac formulations and methods of use |
| 02/27/2008 | EP1890679A2 Steroid kit and foamable composition and uses thereof |
| 02/27/2008 | EP1890678A2 Therapeutic sclerosing foam made preferably xenon |
| 02/27/2008 | EP1890677A2 Pharmaceutical compositions and use thereof |
| 02/27/2008 | EP1890672A1 Use of chromone derivatives |
| 02/27/2008 | EP1890671A1 Use of adamantyl methoxydi phenyl propenoic acid for the treatment of acne |
| 02/27/2008 | EP1890558A1 Novel food ingredient and products containing the same |
| 02/27/2008 | EP1890546A1 A composition to enhance the bioavailability of curcumin |
| 02/27/2008 | EP1890537A1 Methods of treating cancer and other conditions or disease states using lfmau and ldt |
| 02/27/2008 | EP1802307B1 Pyrrolidine derivatives as histamine receptors ligands |
| 02/27/2008 | EP1773810B1 New 4-benzylidene-piperidin derivatives |
| 02/27/2008 | EP1729734B1 Spray dried pharmaceutical compositions |
| 02/27/2008 | EP1716155B1 Substituted thieno- and thiazolo[2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 |
| 02/27/2008 | EP1697356B1 Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| 02/27/2008 | EP1696901B1 The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis in patients with chronic kidney diseases |
| 02/27/2008 | EP1689752B1 Pyrazolopyrimidines |
| 02/27/2008 | EP1689489B1 Peptidically buffered formulations for electrotransport applications and methods of making |
| 02/27/2008 | EP1663273B1 Powdery composition for use as a laxative |
| 02/27/2008 | EP1658053B1 Novel compositions of sildenafil free base |
| 02/27/2008 | EP1633364B1 Processes for the production of sildenafil base and citrate salt |
| 02/27/2008 | EP1610786B9 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's |
| 02/27/2008 | EP1610770B1 Use of an ibat inhibitor for the treatment or prophylaxis of constipation |
| 02/27/2008 | EP1608733A4 Modified polynucleotides for use in rna interference |
| 02/27/2008 | EP1581531B1 Pyridino¬2,3-d pyrimidine derivatives as selectiive kdr and fgfr inhibitors |
| 02/27/2008 | EP1565180A4 A method for inhibiting cancer development by fatty acid synthase inhibitors |
| 02/27/2008 | EP1562955B1 Quinazoline derivatives as src tyrosine kinase inhibitors |
| 02/27/2008 | EP1558616B1 Meso-substituted porphyrins |
| 02/27/2008 | EP1558610B1 Substituted aminoquinuclidine compounds and their use as delta-opioid receptor ligands |
| 02/27/2008 | EP1553944B1 Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist |
| 02/27/2008 | EP1532155B1 C6- AND C9-SUBSTITUTED CHROMENO[4,3-c]ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS |
| 02/27/2008 | EP1509251B1 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 02/27/2008 | EP1506958B1 Process for producing shogaol and intermediates for the synthesis thereof |
| 02/27/2008 | EP1506192B1 Substituted pyrroline kinase inhibitors |
| 02/27/2008 | EP1483266B1 Spiro compounds with npy antagonistic activity |
| 02/27/2008 | EP1476193B1 A weight management system for obese animals |
| 02/27/2008 | EP1471065B1 Novel 1,2,4-triazole compound |
| 02/27/2008 | EP1458364B1 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus |
| 02/27/2008 | EP1450867B1 Sterilizing tunnel for pharmaceutical containers |
| 02/27/2008 | EP1446115B1 Cyanoalkylamino derivatives as protease inhibitors |
| 02/27/2008 | EP1435939B1 Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins |
| 02/27/2008 | EP1406694B1 Electro-medical device for use with biologics |
| 02/27/2008 | EP1399423B9 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds |
| 02/27/2008 | EP1395564B1 Quinoline derivatives as ligands for the neuropeptide y receptor |
| 02/27/2008 | EP1389116B1 Cathartic-inducing composition |
| 02/27/2008 | EP1351685B1 Stabilized formulation of selective ligands of retinoic acid gamma-receptors |
| 02/27/2008 | EP1351666B1 A method for the preparation of nanoparticles |
| 02/27/2008 | EP1341811B1 Orally ingestible preparation of mistletoe lectins and method |
| 02/27/2008 | EP1337263B1 A composition of rose hip and fish oil for alleviating joint pain and stiffness |
| 02/27/2008 | EP1333812B1 Microgranules based on active principle and method for making same |
| 02/27/2008 | EP1329504B1 Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like |
| 02/27/2008 | EP1318994B1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 02/27/2008 | EP1317409B1 Method for the purification of an alpha-hydroxy acid on an industrial scale |
| 02/27/2008 | EP1311300B1 Radioligand and binding assay |
| 02/27/2008 | EP1282700B1 Neuronal serine-threonine protein kinase |
| 02/27/2008 | EP1268470B1 Dual molecules containing a peroxide derivative, synthesis and therapeutic applications thereof |
| 02/27/2008 | EP1248612B1 Novel compounds and compositions as protease inhibitors |
| 02/27/2008 | EP1246806B1 Arly- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 02/27/2008 | EP1194139B1 Nutritional composition for weight management |
| 02/27/2008 | EP1150959B1 Solid-state form of celecoxib having enhanced bioavailability |
| 02/27/2008 | EP1149105B1 4,5-pyrazinoxindoles as protein kinase inhibitors |
| 02/27/2008 | EP1141278B1 Therapeutic pde4d phosphodiesterase inhibitors |
| 02/27/2008 | EP1089740B1 Compositions for the treatment of cdad initiated by c. difficile toxin b |
| 02/27/2008 | EP1039906B1 metal complexes with antibacterian and fungicidal effects |